If you were born after 1960, there’s a 50% chance you’ll get cancer at some point in your life which, to be quite honest, pretty much sucks to hear. Studies have been coming out for decades about the risks of cancer, but recent articles published by many sources (April 1, 2015 MensHealth we’ll be referring to) and the shift of attitude towards the silent killer has made many investors extremely rich by investing in these cure finders, especially the penny stocks in the field. One particular cancer researcher, Propanc Health Group (OTC: PPCH), has been a stellar performer at times as their aggressive approach to treating, among many, pancreatic cancer has placed them within a small group of tickers traders should be familiar with.
After announcing last month their intentions to start cleaning up the toxic debt on their books and reduce the total number of shares issuable, PPCH stock has not only gained over 100% since the move, but having been a 10 bagger plus on multiple occasions, it could be in for a solid EOY run. Considering how Advaxis Inc. (NASDAQ: ADXS) and OncoSec Medical Inc. (NASDAQ: ONCS) were in this boat 2-3 years ago, the mere mention of uplisting in the coming years could be a blockbuster buy for those with long expectations.
Find out more about PPCH shares here: $PPCH
Propanc Health Group is an Australian based development stage biotech company that, since it began in 2007, has been focused on new cancer treatments targeting high risk patients who need a follow up, nontoxic, long term therapy which prevents the cancer from returning and spreading. During their course to find a cure, the Company, as of March 31, 2015, had incurred losses of $19,139,084 which, like all others researching for cures, had to find ways to get funds loaned to them, some of which were not favorable for shareholders.
Back in June, the Company posted a shareholder update after having been a presenter at the SeeThru Equity Conference, not one which many penny stock traders have had much confidence in. However, following the update which mentioned the successes they have had in their studies on mice, the move into the next phase of testing their PRP on other live subjects, eventually leading up to human clinical trials, is a matter which, after this long, should not be taken lightly.
Understanding the mechanics of building back investor confidence in PPCH, the Company took the first step by repaying $120,599.29 of toxic debt which was held by KBM Worldwide Inc. and Carebourn Capital. Sure, it may only be roughly 10% of the $1,138,184 in net convertible notes that were on the books as of March 31, 2015, but their move last month to reduce their authorized share count from 10 billion to 2 billion showed another step in the right direction in rebuilding that confidence.
Toxic debt on a company’s books can be compared to the 53.5% chance that men born after 1960 in the UK will develop some form of cancer in their lifetime. While it might remain their dormant throughout the lifespan of the note agreement, as soon as the terms are beneficial enough for the lender, converting them into cheap shares and crushing the hopes and dreams of retail investors is almost equally life threatening for the ticker as getting cancer is for a person.
Researchers suggest that not using tobacco, being active, maintaining a healthy weight, and eating a diet high in fruits and vegetables and low in processed food are all things that can keep your lifetime cancer risk lower than the numbers predict. With the efforts that have been made thus far this summer by Propanc Health Group, a remission of dumpage on PPCH shares could be just what the doctor ordered for this 7 time multi bagger since November, 2014 to begin another run past 0.10.
We are 100% Anti-Spam and will never rent or sell your information.
Many of our picks go up 100%, 200%, even 10,000%, see for yourself.
[gravityform id=”6″ name=”Post” title=”false”]Share